Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.56 |
| ▸ | MPC2 | O95563 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016492 | 0.87 | PPARG (0.57) | PPARGFFAR1CYP3A4RXRAPPARA | |
| SCHEMBL6931816 | 0.81 | FFAR1 (0.66) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6931105 | 0.80 | PPARG (0.70) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4857392 | 0.79 | PPARG (0.52) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL14197265 | 0.79 | PPARG (0.56) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL13846731 | 0.79 | CA2 (0.64) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL8981939 | 0.78 | KDM4E (0.66) | PPARGMPC2CYP2C8CYP2C9CA2 | |
| SCHEMBL8981935 | 0.78 | KDM4E (0.66) | PPARGMPC2CYP2C8CYP2C9CA2 | |
| SCHEMBL8981926 | 0.78 | KDM4E (0.66) | PPARGMPC2CYP2C8CYP2C9CA2 | |
| SCHEMBL13846771 | 0.78 | CA2 (0.63) | PPARGMPC2CYP2C8CYP2C9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159463-A1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-07-21 | — | — | US | claimed |
| EP-1189583-B1 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2005-07-20 | — | — | EP | claimed |
| EP-1189583-A4 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2004-04-14 | — | — | EP | claimed |
| EP-1189583-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2002-03-27 | — | — | EP | claimed |
| WO-2000072815-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2000-12-07 | — | — | WO | claimed |
| US-7355054-B2 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-04-08 | — | — | US | disclosed |
| US-20050159463-A1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-07-21 | — | — | US | disclosed |
| EP-1189583-B1 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2005-07-20 | — | — | EP | disclosed |
| US-6858642-B1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-02-22 | — | — | US | disclosed |
| EP-1189583-A4 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2004-04-14 | — | — | EP | disclosed |
| EP-1189583-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000072815-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159463-A1 | Indole derivatives | IDO1, IDO2, H1-0 | PPARG 2410/4885MPC2 3825/4885CYP2C8 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.